(Q37882459)

24 August 2017

1 reference

title

Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I. (English)

1 reference

24 August 2017

0 references

3

1 reference

24 August 2017

Jacek Wilczynski

1

1 reference

24 August 2017

Markus Duechler

series ordinal

2

1 reference

24 August 2017

publication date

28 May 2011

1 reference

Archivum Immunologiae et Therapiae Experimentalis

24 August 2017

published in

1 reference

24 August 2017

volume

59

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

289-299

1 reference

Nuclear factor-kappaB: the enemy within

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Nuclear factor-kappa B: from clone to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Thalidomide analogues as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Mechanism of hypoxia-induced NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase II trial of curcumin in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Adverse effects of thalidomide administration in patients with neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Evodiamine, a constituent of Evodiae Fructus, induces anti‐proliferating effects in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

New regulators of NF-kappaB in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Missing pieces in the NF-kappaB puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Inhibitors of NF-kappaB signaling: 785 and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

The IKK complex, a central regulator of NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

The IkappaB kinase - a bridge between inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Breast cancer and NSAID use: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappa B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

NF-kappaB as a potential molecular target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Identification of nuclear export inhibitors with potent anticancer activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

NF-kappaB and cancer-identifying targets and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Activators and target genes of Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

NF-kappaB: tumor promoter or suppressor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

IkappaB kinase complexes: gateways to NF-kappaB activation and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Nuclear factor-kappaB activation: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Emerging roles for the non-canonical IKKs in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Nuclear factor-kappaB: a friend or a foe in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Prostaglandins and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-011-0131-4

10.1007/S00005-011-0131-4

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference